Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Rivaroxaban Roundup: NEJM Perspective on FDA Panel, ATLAS-ACS Will Be an AHA Late-Breaker
Rivaroxaban Roundup: NEJM Perspective on FDA Panel, ATLAS-ACS Will Be an AHA Late-Breaker
Rivaroxaban Roundup: NEJM Perspective on FDA Panel, ATLAS-ACS Will Be an AHA Late-Breaker
Submitted by
admin
on October 6, 2011 - 9:18am
Source:
Forbes
News Tags:
FDA
rivaroxaban
Xarelto
Bayer
JNJ
Headline:
Rivaroxaban Roundup: NEJM Perspective on FDA Panel, ATLAS-ACS Will Be an AHA Late-Breaker
Do Not Allow Advertisers to Use My Personal information
